---
title: <em>ASXL1</em> mutations are associated with a response to alvocidib and 5-azacytidine
  combination in myelodysplastic neoplasms
date: '2023-11-02'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/37916386/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20231102180753&v=2.17.9.post6+86293ac
source: heidelberg[Affiliation]
description: Inhibitors of anti-apoptotic BCL-2 family proteins in combination with
  chemotherapy and hypomethylating agents (HMAs) are promising therapeutic approaches
  in acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS). Alvocidib,
  a cyclin-dependent kinase 9 (CDK9) inhibitor and indirect transcriptional repressor
  of the anti-apoptotic factor MCL-1, has previously shown clinical activity in AML.
  Availability of biomarkers for response to the alvocidib + 5- AZA could also extend
  ...
disable_comments: true
---
Inhibitors of anti-apoptotic BCL-2 family proteins in combination with chemotherapy and hypomethylating agents (HMAs) are promising therapeutic approaches in acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS). Alvocidib, a cyclin-dependent kinase 9 (CDK9) inhibitor and indirect transcriptional repressor of the anti-apoptotic factor MCL-1, has previously shown clinical activity in AML. Availability of biomarkers for response to the alvocidib + 5- AZA could also extend ...